4basebio PLC

Latest Results (09.11.2025):

4basebio PLC has released its unaudited half-yearly financial results for H1 2021, covering the six months ended 30 June 2021. The results show a modest increase in revenue from £0.16 million in H1 2020 to £0.18 million in H1 2021, alongside a widened loss reflecting higher operating expenditures. The company ended the period with cash balances of £12.1 million and a net cash outflow from operating activities of £1.7 million, as it continues to invest in its DNA synthesis and non-viral vector technologies while advancing key operational initiatives, including the conversion to PLC status and the build-out of a DNA manufacturing facility.

Revenue & Earnings

For H1 2021, 4basebio PLC reported revenue of £0.18 million, up from £0.16 million in the prior year, while the loss for the period widened to £1.7 million compared to a loss of £0.38 million in H1 2020. Operating cash outflow increased to £1.7 million from £0.51 million in H1 2020.

Operational Progress

The Group achieved significant milestones including transitioning to PLC status following shareholder approval, initiating construction of a DNA manufacturing facility expected to be completed by year end, and achieving positive validation studies comparing their synthetic DNA to plasmid DNA. Additionally, multiple patent filings have been made across its DNA synthesis and nanoparticle delivery technologies, and collaboration licence agreements have been signed, notably with Royal Holloway.

Cash Position & Strategic Outlook

4basebio PLC ended H1 2021 with a cash balance of £12.1 million, providing a runway into 2023 before the need to draw upon its debt facility. The company remains focused on scaling up its manufacturing capabilities and accelerating research and development, in anticipation of commencing DNA sales in 2022 while managing ongoing pre-revenue expenditure.